Form 4: Cytokinetics EVP, Chief Commercial Officer Andrew Callos Sells Shares to Cover Restricted Stock Unit Vesting

Andrew Callos, EVP, Chief Commercial Officer of Cytokinetics Inc, sold 1,114 shares of common stock on March 3, 2025, to cover a transaction related to the vesting of restricted stock units.

Summary

• On March 3, 2025, Andrew Callos, the EVP, Chief Commercial Officer of Cytokinetics Inc., sold 1,114 shares of the company's common stock.
• The sale was executed at a price of $42.88 per share.
• The transaction was conducted to cover obligations related to the vesting of restricted stock units.
• Following the transaction, Callos directly owns 67,775 shares of Cytokinetics Inc.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing a stock sale by an officer to cover RSU vesting, which is a neutral event.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, trade their company's stock. These filings provide transparency into insider transactions and can be used by investors to gauge management's sentiment about the company's prospects.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to be significant given the context of RSU vesting.

Key Dates